<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136105">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01801280</url>
  </required_header>
  <id_info>
    <org_study_id>CERL 080A DE 20 T</org_study_id>
    <secondary_id>2010-021275-92</secondary_id>
    <nct_id>NCT01801280</nct_id>
  </id_info>
  <brief_title>Influence of Pantoprazole to the Bioavailability of Myfortic® and CellCept®</brief_title>
  <official_title>Single Center, Open Label, Cross-over Study in Maintenance Renal Transplant Patients to Evaluate the Bioavailability of CellCept® (Mycophenolate Mofetil) in Comparison to Myfortic® (Enteric Coated Mycophenolate Sodium) With/Without the Proton Pump Inhibitor Pantozol® (Pantoprazole).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klemens Budde</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The object of this pharmakokinetic study is to analyze wether pantoprazole as a proton pump
      inhibitor influences the bioavailability of two different tablet formulations of
      mycophenolic acid applied either as mycophenolate mofetil or mycophenolate Sodium.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Bioavailability of mycophenolic acid (measured by AUC)</measure>
    <time_frame>Study duration for each patient: 2 months. After 10-14 days of drug intake blood samples for full AUC will be collected and on the next day new treatment starts. Every patient has to visit the study centre four times for approximately 12 hours.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation of the bioavailability (as measured by 12h AUC) of mycophenolic acid in stable renal transplant patients under immunosuppressive maintenance therapy after application of CellCept® alone or in combination with Pantozol®; Myfortic® alone or in combination with Pantozol®.
For pharmacokinetic and pharmacodynamic parameters 12 samples (before, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h after oral drug administration) from venous blood will be collected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of additional pharmacokinetic parameters</measure>
    <time_frame>Study duration for each patient: 2 months. After 10-14 days of drug intake blood samples for full AUC will be collected and on the next day new treatment starts. Every patient has to visit the study centre four times for approximately 12 hours.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analysis of additional pharmacokinetic parameters, such as maximum concentration, average concentration, minimum concentration, time to Cmax, apparent clearance of mycophenolic acid and its metabolite mycophenolic acid glucuronide.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of pharmacodynamic parameters</measure>
    <time_frame>Study duration for each patient: 2 months. After 10-14 days of drug intake blood samples for full AUC will be collected and on the next day new treatment starts. Every patient has to visit the study centre four times for approximately 12 hours.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analysis if IMPDH activity and the related pharmacodynamic parameters as maximum activity, minimum activity, average activity, maximum inhibition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of safety and tolerability</measure>
    <time_frame>Study duration for each patient: 2 months. After 10-14 days of drug intake every patient has to visit the study center 4 times for approximately 12 hours.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Analysis of safety and tolerability, in particular analysis of gastrointestinal discomfort (using two standardized questionnaires), infections, leucopenia, anemia, thrombocytopenia, renal function using serum creatinine and glomerular filtration rate (Cockcroft-Gault), ciclosporin blood levels (before and two hours after administration), incidence of biopsy-proven acute rejections and graft loss.
Before oral drug administration additionally blood samples for blood chemistry, hematology and urine for urinalysis will be collected.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Immunosuppressive Medication After Renal Transplantation</condition>
  <condition>Concomitant Medication After Renal Transplantation</condition>
  <arm_group>
    <arm_group_label>C→ M → M+ P → C + P</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Mycophenolate mofetil (C) tablet twice a day every 12 hours for two weeks. Mycophenolate sodium (M) tablet twice a day every 12 hours for two weeks. Pantoprazole tablet (P) once a day in the morning for two weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M → M + P → C + P → C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Mycophenolate mofetil (C) tablet twice a day every 12 hours for two weeks. Mycophenolate sodium (M) tablet twice a day every 12 hours for two weeks. Pantoprazole tablet (P) once a day in the morning for two weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M + P→ C + P → C→ M</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Mycophenolate mofetil (C) tablet twice a day every 12 hours for two weeks. Mycophenolate sodium (M) tablet twice a day every 12 hours for two weeks. Pantoprazole tablet (P) once a day in the morning for two weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C+ P→ C → M→ M+ P</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Mycophenolate mofetil (C) tablet twice a day every 12 hours for two weeks. Mycophenolate sodium (M) tablet twice a day every 12 hours for two weeks. Pantoprazole tablet (P) once a day in the morning for two weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate sodium</intervention_name>
    <description>Daily dose: 720mg, 1080mg, 1440mg. Application either alone or together with Pantozol®.</description>
    <arm_group_label>C→ M → M+ P → C + P</arm_group_label>
    <arm_group_label>M → M + P → C + P → C</arm_group_label>
    <arm_group_label>M + P→ C + P → C→ M</arm_group_label>
    <arm_group_label>C+ P→ C → M→ M+ P</arm_group_label>
    <other_name>Myfortic®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole</intervention_name>
    <description>Daily dose: 40mg. Application together with either CellCept® or Myfortic® .</description>
    <arm_group_label>C→ M → M+ P → C + P</arm_group_label>
    <arm_group_label>M → M + P → C + P → C</arm_group_label>
    <arm_group_label>M + P→ C + P → C→ M</arm_group_label>
    <arm_group_label>C+ P→ C → M→ M+ P</arm_group_label>
    <other_name>Pantozol®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Daily dose: 1000mg, 1500mg, 2000mg. Application either alone or with Pantozol® .</description>
    <arm_group_label>C→ M → M+ P → C + P</arm_group_label>
    <arm_group_label>M → M + P → C + P → C</arm_group_label>
    <arm_group_label>M + P→ C + P → C→ M</arm_group_label>
    <arm_group_label>C+ P→ C → M→ M+ P</arm_group_label>
    <other_name>Cellcept®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients &gt;18 years old

          -  patients who are on stable immunosuppressive pre-treatment for at least one month
             with Cyclosporin A, Myfortic® or CellCept® with/without corticosteroids

          -  renal transplantation, at least 6 months prior study inclusion

          -  suitable and willing to switch treatment according to the study plan

          -  women of childbearing potential must have a negative serum pregnancy test before
             study start and effective contraception must be used (method with PEARL index &lt; 1%)

        Exclusion Criteria:

          -  patients with renal function &lt; 30ml/min (using Cockcroft Gault formula)

          -  patients who are not on stable treatment with enzyme inductors or enzymes for one
             month before study start

          -  known anamnestic hypersensitivity to one of the investigational products or drugs
             with similar chemical structure and to other components of the investigational
             products, respectively

          -  patients on treatment with clopidogrel

          -  acute rejection &lt; 1 month before study inclusion

          -  patients who are HIV positive, hepatitis C virus (HCV) positive, HBsAg positive

          -  patients with gastrointestinal disorders which could affect resorption

          -  pregnancy and/or lactation

          -  drug or alcohol abuse in patient's history

          -  patients with a history of psychological illness or condition, so it might interfere
             with the patient's ability to understand the requirements, consequences, possible
             outcome of the study and patients who are not willing to give valid informed consent
             to the study

          -  patients with insufficient co-operation with the clinical investigator (e.g.
             suspicion of non-compliance)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klemens Budde, Prof Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Klemens Budde, Prof Dr</last_name>
    <phone>+49 30 450 154 086</phone>
    <email>klemens.budde@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olesja Rissling</last_name>
    <phone>+49 30 450 154 125</phone>
    <email>olesja.rissling@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité Hospital Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klemens Budde, Prof Dr</last_name>
      <phone>+49 30 450 154 086</phone>
      <email>klemens.budde@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Olesja Rissling</last_name>
      <phone>+49 30 450 154 125</phone>
      <email>olesja.rissling@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Klemens Budde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 26, 2013</lastchanged_date>
  <firstreceived_date>February 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Klemens Budde</investigator_full_name>
    <investigator_title>Professor Dr Klemens Budde</investigator_title>
  </responsible_party>
  <keyword>immunosuppressive medication</keyword>
  <keyword>mycophenolic acid</keyword>
  <keyword>interaction</keyword>
  <keyword>proton pump inhibitor</keyword>
  <keyword>pantoprazole</keyword>
  <keyword>renal transplant patients</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>bioavailability</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mycophenolate mofetil</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Pantoprazole</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
